You are here:

Archived: salmeterol fluticasone 50/500 micrograms inhaler (Seretide 500 Accuhaler)

Advice

Following a full submission

salmeterol/fluticasone 50/500 microgram inhaler (Seretide 500 Accuhaler) is not recommended for use within NHS Scotland for the symptomatic treatment of patients with chronic obstructive airways disease (COPD) with a forced expiratory volume in 1 second (FEV1) 50% to <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

While there was an improvement in lung function tests and a reduction in both moderate and severe exacerbations with salmeterol/fluticasone in comparison with placebo, there was no difference in mortality rate over 3 years. In addition, the manufacturer did not present a sufficiently robust economic case to gain acceptance by SMC.

Drug Details

Drug Name: salmeterol fluticasone 50/500 micrograms inhaler (Seretide 500 Accuhaler)
SMC Drug ID: 450/08
Manufacturer: GlaxoSmithKline UK Ltd
Indication: For the symptomatic treatment of patients with chronic obstructive pulmonary disease (COPD)
BNF Category:
Sub Category: 3.1 Bronchodilators
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 10 March 2008

Current Advice

Resubmission 12 January 2009

Back